Trying to find info on the drug DB102, which Denovo acquired from Ely Lily. Can't find anything that indicates it crosses BBB.
From their website:
DB102: Anti-tumor Drug EnzastaurinLilly conducted many clinical studies with enzastaurin in a variety of tumor indications, including Phase 3 clinical trials in diffuse large B cell lymphoma (DLBCL) and glioma (GBM), and has received orphan drug certification in the U.S. and Europe. Denovo acquired global rights to enzastaurin from Lilly, including development, production and commercialization. Denovo has completed the identification of the biomarker, which is significantly correlated with the expected therapeutic effects on DLBCL and GBM patients, and has filed international patent applications. Denovo initiated a pivotal Phase 3 global DLBCL clinical trial in 2018 with data readout expected in mid-2021. In 2018 Denovo licensed the rights to use DB102 for Pulmonary Arterial Hypertension (PAH) from Stanford University.
KZA Price at posting:
50.0¢ Sentiment: Buy Disclosure: Held
